Evidence map›Paper›PMID 42238824›Full record

ReviewRegenerative therapy2026

Unapproved regenerative medicine for spinal cord injury in Japan.

Yuichiro Ukon, Hideyuki Hakui, Satoshi Hosoya, Kazuki Morita, Hirokazu Mae, Yuya Kanie, Masayuki Furuya, Takahito Fujimori, Kiyoshi Okada, Akira Myoui and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuichiro UkonX-innovation Committee for Health and Medical, The University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Hideyuki HakuiResearch and Development Policy Division, Health Policy Bureau, Ministry of Health, Labour and Welfare, 1-2-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-8916, Japan.
Satoshi HosoyaDepartment of Obstetrics and Gynecology, Jikei University School of Medicine, 3-25-8, Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Kazuki MoritaDepartment of Periodontology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (Science Tokyo), 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Hirokazu MaeDepartment of Medical Innovation, The University of Osaka University Hospital, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Yuya KanieDepartment of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Masayuki FuruyaDepartment of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Takahito FujimoriDepartment of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Kiyoshi OkadaX-innovation Committee for Health and Medical, The University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Akira MyouiDepartment of Medical Innovation, The University of Osaka University Hospital, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
Seiji OkadaDepartment of Orthopaedic Surgery, The University of Osaka Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study presented an overview of unapproved regenerative medicine for spinal cord injury (SCI) in Japan under the Act on the Safety of Regenerative Medicine. In total, 41 non-research regenerative medicine provision plans were identified. Three plans (7%) specified administration exclusively during the chronic phase, whereas remaining plans did not state the period. Most therapies used adipose-derived (68%) or bone marrow-derived (32%) mesenchymal stem cells. The most common administration route was intravenous (71%), followed by intrathecal (27%). Culture periods were typically around four weeks, and the most frequently administered cell dose was 1.0 × 10

Indexed as

RM ActSpinal cord injuryUnapproved regenerative medicine

Identifiers

PMID42238824
PMCPMC13226842

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.